Penny Powers

1.0k total citations
13 papers, 372 citations indexed

About

Penny Powers is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Penny Powers has authored 13 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cancer Research, 6 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Penny Powers's work include Breast Cancer Treatment Studies (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Epigenetics and DNA Methylation (3 papers). Penny Powers is often cited by papers focused on Breast Cancer Treatment Studies (5 papers), Histone Deacetylase Inhibitors Research (3 papers) and Epigenetics and DNA Methylation (3 papers). Penny Powers collaborates with scholars based in United States. Penny Powers's co-authors include Vered Stearns, Suzanne Lemler, David A. Flockhart, Dennis C. Ang, Daniel F. Hayes, N. Lynn Henry, Lang Li, Dina Dadabhoy, Jill A. Hayden and Jon T. Giles and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Penny Powers

13 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Penny Powers United States	6	152	122	80	72	49	13	372
Hela Ben Nasr Tunisia	15	95 0.6×	44 0.4×	144 1.8×	149 2.1×	90 1.8×	33	484
Romana Illig Austria	16	89 0.6×	37 0.3×	65 0.8×	214 3.0×	60 1.2×	28	502
Stefan‐Martin Brand‐Herrmann Germany	12	40 0.3×	66 0.5×	36 0.5×	190 2.6×	26 0.5×	22	470
Liang Chang China	11	66 0.4×	19 0.2×	52 0.7×	121 1.7×	44 0.9×	18	333
Andrea De Censi Italy	10	186 1.2×	62 0.5×	62 0.8×	150 2.1×	34 0.7×	39	349
Ming-Nan Chien Taiwan	13	68 0.4×	73 0.6×	33 0.4×	108 1.5×	28 0.6×	31	388
Maria Inês Alvelos Belgium	13	48 0.3×	191 1.6×	42 0.5×	215 3.0×	32 0.7×	20	479
Kiriko Wada Japan	11	57 0.4×	95 0.8×	39 0.5×	146 2.0×	19 0.4×	21	413
Fuye Yang China	8	45 0.3×	38 0.3×	60 0.8×	286 4.0×	65 1.3×	9	576
Shenglei Zhang China	12	33 0.2×	32 0.3×	56 0.7×	161 2.2×	67 1.4×	43	348

Countries citing papers authored by Penny Powers

Since Specialization

Citations

This map shows the geographic impact of Penny Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penny Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penny Powers more than expected).

Fields of papers citing papers by Penny Powers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penny Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penny Powers. The network helps show where Penny Powers may publish in the future.

Co-authorship network of co-authors of Penny Powers

This figure shows the co-authorship network connecting the top 25 collaborators of Penny Powers. A scholar is included among the top collaborators of Penny Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penny Powers. Penny Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Connolly, Roisín M., Rachel C. Jankowitz, Cynthia A. Zahnow, et al.. (2014). Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.. Journal of Clinical Oncology. 32(15_suppl). 569–569. 1 indexed citations

Stearns, Vered, Lisa K. Jacobs, Theodore N. Tsangaris, et al.. (2013). Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer. Clinical Cancer Research. 19(14). 4008–4016. 24 indexed citations

Bardia, Aditya, Cesar Augusto Santa-Maria, Lisa K. Jacobs, et al.. (2013). Digoxin as an inhibitor of global hypoxia inducible factor-1α (HIF1α) expression and downstream targets in breast cancer: Dig-HIF1 pharmacodynamic trial.. Journal of Clinical Oncology. 31(15_suppl). TPS1144–TPS1144. 3 indexed citations

Connolly, Roisín M., Rachel C. Jankowitz, Cynthia A. Zahnow, et al.. (2013). Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer.. Cancer Research. 73(8_Supplement). 4666–4666. 10 indexed citations

Connolly, Roisín M., Jeffrey P. Leal, Matthew P. Goetz, et al.. (2012). Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).. Journal of Clinical Oncology. 30(15_suppl). 10509–10509. 4 indexed citations

Jelovac, Danijela, Brian Blair, Shannon A. Slater, et al.. (2011). Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 10512–10512. 3 indexed citations

Stearns, Vered, Tsuyoshi Mori, Lisa K. Jacobs, et al.. (2011). Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer. Science Translational Medicine. 3(106). 106ra108–106ra108. 65 indexed citations

Stearns, Vered, Lisa K. Jacobs, Nagi F. Khouri, et al.. (2009). A phase 1 study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women awaiting mastectomy. BMC Proceedings. 3(S5). 3 indexed citations

Jacobs, Lisa K., Nagi F. Khouri, Stacie C. Jeter, et al.. (2009). A phase I study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women with breast cancer. Journal of Clinical Oncology. 27(15_suppl). e11506–e11506. 1 indexed citations

10.

Carraway, Hetty E., Amanda L. Blackford, Penny Powers, et al.. (2008). Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence. Breast Cancer Research and Treatment. 114(2). 315–325. 7 indexed citations

11.

Sukumar, Saraswati, Vered Stearns, Nagi F. Khouri, et al.. (2008). Abstract CN13-03: Intraductal route of breast cancer prevention and therapy: from preclinical studies to Phase I trials. Cancer Prevention Research. 1(7_Supplement). CN13–3. 1 indexed citations

12.

Henry, N. Lynn, Jon T. Giles, Dennis C. Ang, et al.. (2007). Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Research and Treatment. 111(2). 365–372. 187 indexed citations

13.

Lewis, Richard A., Charles Van Buren, Carl M. Sandler, et al.. (1989). COMPARATIVE EVALUATION OF UROGRAPHIC CONTRAST MEDIA, INULIN, AND 99mTc-DTPA CLEARANCE METHODS FOR DETERMINATION OF GLOMERULAR FILTRATION RATE IN CLINICAL TRANSPLANTATION. Transplantation. 48(5). 790–795. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact